Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations

PHASE4CompletedINTERVENTIONAL
Enrollment

455

Participants

Timeline

Start Date

September 25, 2023

Primary Completion Date

March 7, 2024

Study Completion Date

May 17, 2024

Conditions
InfluenzaCOVID-19
Interventions
BIOLOGICAL

Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster)

Influenza vaccination and mRNA COVID-19 booster will be given at Visit 1.

BIOLOGICAL

Sequential Vaccination (Influenza vaccine then mRNA COVID booster)

Influenza vaccine will be given at Visit 1 and mRNA COVID booster will be given at Visit 2.

BIOLOGICAL

Sequential Vaccination (mRNA COVID booster then Influenza vaccine)

mRNA COVID booster will be given at Visit 1 and Influenza vaccine will be given at Visit 2.

Trial Locations (8)

15260

Department of Family Medicine, University of Pittsburgh School of Medicine, Pittsburgh

30333

Centers for Disease Control and Prevention, Atlanta

44106

University Hospitals Cleveland Medical Center, Cleveland

VA Northeast Ohio Healthcare System (VANEOHS), Cleveland

44121

Senders Pediatrics, South Euclid

63110

Washington University IDCRU, St Louis

85008

Valleywise Health Comprehensive Health Center, Phoenix

85281

ASU Biodesign Institute, Tempe

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Centers for Disease Control and Prevention

FED

collaborator

Arizona State University

OTHER

collaborator

University Hospitals Cleveland Medical Center

OTHER

collaborator

University of Pittsburgh

OTHER

collaborator

Washington University School of Medicine

OTHER

collaborator

Valleywise Health

OTHER

collaborator

Cleveland VA Medical Center

UNKNOWN

collaborator

Senders Pediatrics

UNKNOWN

lead

Duke University

OTHER

NCT06020118 - Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations | Biotech Hunter | Biotech Hunter